Transcription unit and use thereof in (YB2/0) expression vectors
WO2013060995A1
Method for preparing human factor h
FR2995213A1
Syringe containing a composition, especially pharmaceutical, comprising immunoglobulins, method for producing the same and use thereof
WO2013017555A1
Factor vii compositions with specific glycosylation for controlled half-life
WO2012175874A1
Use of a high-adcc anti-cd20 antibody for treating waldenström's macroglobulemia
FR2990441A1
Preparing infectious material to purify blood product comprises cultivating cells expressing prion proteins and supporting replication of pathogenic form of protein, incubating cells without nutritional intake, and collecting cell lysate
FR2986536A1
Transcription units and their use in expression vectors (cho)
FR2984750A1
NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A HUMAN RECEPTOR ANTIBODY OF ANTI-MULLERIAN HORMONE TYPE II
FR2983212A1
Anti-fh aptamers, process for obtaining them and uses thereof
FR2981651A1
Method for immobilization of nucleic ligands
FR2980110A1
Composition, useful for treating tumor including malignant tumor, leukemia and non-Hodgkin lymphoma, comprises bendamustine and an anti-cluster of differentiation 20 antibody, which is a monoclonal antibody
EP2554161A1
Pharmaceutical composition comprising factor VII encapsulated in micelles
EP2566511A2
Use of an anti-cd71 antibody for preparing a medicament
FR2970417A1
Kit, useful as a drug for treating severe sepsis or septic shock, comprises protein C and alpha-1-antitrypsin
FR2969761A1
Method of assaying antibodies directed against factor viii
FR2966043A1
Use of anti-cd20 antibody for the treatment of primitive cerebral lymphoma
FR2962908A1
Anti-cd20 antibody formulation
FR2962439A1
Monoclonal antibodies against tetanic toxin
FR2959994A1
NOVEL 12G4 MUTUS HUMANIZED ANTIBODIES AND THEIR FRAGMENTS DIRECTED AGAINST THE HUMAN TYPE II ANTI-MULLERIAN HORMONE RECEPTOR
